CL2017000636A1 - Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores - Google Patents

Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores

Info

Publication number
CL2017000636A1
CL2017000636A1 CL2017000636A CL2017000636A CL2017000636A1 CL 2017000636 A1 CL2017000636 A1 CL 2017000636A1 CL 2017000636 A CL2017000636 A CL 2017000636A CL 2017000636 A CL2017000636 A CL 2017000636A CL 2017000636 A1 CL2017000636 A1 CL 2017000636A1
Authority
CL
Chile
Prior art keywords
veliparib
carboplatin
paclitaxel
treatment
combination
Prior art date
Application number
CL2017000636A
Other languages
English (en)
Inventor
Vincent Giranda
Gary Gordon
Mark D Mckee
Jane Qian
Qin Qin
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CL2017000636A1 publication Critical patent/CL2017000636A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>MÉTODO PARA TRATAR EL CÁNCER PULMONAR NO MICROCÍTICO EN UN SUJETO QUE ES UN FUMADOR, QUE COMPRENDE ADMINISTRARLE AL SUJETO UNA CANTIDAD EFICAZ DE 2-[(2R)-2-METILPIRROLIDIN-2-IL]-1H-BENZIMIDAZOL-4-CARBOXAMIDA (VELIPARIB O ABT-888), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ÉSTA, EN COMBINACIÓN CON CARBOPLATINO Y PACLITAXEL.</p>
CL2017000636A 2014-09-16 2017-03-15 Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores CL2017000636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462051040P 2014-09-16 2014-09-16

Publications (1)

Publication Number Publication Date
CL2017000636A1 true CL2017000636A1 (es) 2017-11-03

Family

ID=54207780

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000636A CL2017000636A1 (es) 2014-09-16 2017-03-15 Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores

Country Status (15)

Country Link
US (2) US9623009B2 (es)
EP (1) EP3193861A1 (es)
JP (1) JP2017527627A (es)
KR (1) KR20170055536A (es)
CN (1) CN107073015B (es)
AU (1) AU2015317856B2 (es)
CA (1) CA2959175A1 (es)
CL (1) CL2017000636A1 (es)
DO (1) DOP2017000069A (es)
IL (1) IL250708A0 (es)
MX (1) MX2017003304A (es)
PH (1) PH12017500505A1 (es)
RU (1) RU2017112960A (es)
SG (1) SG11201702129XA (es)
WO (1) WO2016044384A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7033601B2 (ja) * 2017-01-05 2022-03-10 コリア リサーチ インスティチュート オブ バイオサイエンス アンド バイオテクノロジー 抗コチニンキメラ抗原受容体を発現するナチュラルキラー細胞
WO2018187485A1 (en) * 2017-04-04 2018-10-11 The George Washington University Combination therapy for treating cancer
US20200129482A1 (en) * 2017-06-26 2020-04-30 Abbvie Inc. Treatment of non-small cell lung cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
CA2764234C (en) * 2009-06-04 2019-03-12 The Governors Of The University Of Alberta Small molecule inhibitors of polynucleotide kinase/phosphatase, poly(adp-ribose) polymerase and uses thereof
RU2014150506A (ru) * 2012-05-15 2016-07-10 Эббви Инк. Велипариб в комбинации с лучевой терапией всего мозга для лечения метастазов в головной мозг
EP2879712B1 (en) * 2012-07-31 2018-04-25 Crown Bioscience, Inc. (Taicang) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
US20140187537A1 (en) * 2013-01-03 2014-07-03 Emory University Methods of predicting outcomes of chemotherapy treatments and alternative therapies

Also Published As

Publication number Publication date
EP3193861A1 (en) 2017-07-26
WO2016044384A1 (en) 2016-03-24
MX2017003304A (es) 2017-08-15
SG11201702129XA (en) 2017-04-27
AU2015317856B2 (en) 2020-05-14
US20170172985A1 (en) 2017-06-22
KR20170055536A (ko) 2017-05-19
CN107073015B (zh) 2020-07-21
JP2017527627A (ja) 2017-09-21
IL250708A0 (en) 2017-04-30
CA2959175A1 (en) 2016-03-24
US9623009B2 (en) 2017-04-18
CN107073015A (zh) 2017-08-18
US20160074368A1 (en) 2016-03-17
DOP2017000069A (es) 2017-05-15
AU2015317856A1 (en) 2017-03-16
RU2017112960A (ru) 2018-10-17
PH12017500505A1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
GT201500263A (es) Inhibidores de cdc7
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
CL2017000050A1 (es) Terapia de combinación para el cáncer
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
DOP2017000111A (es) Inhibidor de cinasa aurora a
DOP2017000098A (es) Compuesto heterocíclico
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
CL2017000636A1 (es) Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores
PH12016501101A1 (en) Veliparib in combination with carboplatin for the treatment of triple negative breast cancer
EA201891008A2 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
AR099416A1 (es) Terapia combinada para la hipertensión resistente
EA201690445A1 (ru) Лечение рака
PH12016502284A1 (en) Cough medicine containing ambroxol hydrochloride
DOP2014000258A (es) Tratamiento de la metástasis en el cerebro con una combinación de veliparib y una terapia con radiación en la totalidad del cerebro
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c